Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

CGEM·NASDAQ

$15.21

-0.85%
HealthcareMedical - Pharmaceuticals

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

At a Glance

Live Snapshot
Market Cap$934.78M
EPS-3.7200
P/E Ratio-4.09
Earnings Date08/06/2026

cgem

Cash and Cash Equivalents

Last Annual Value

88.33M

3-Year CAGR

-17%

5-Year CAGR

-12%

10-Year CAGR

10%

Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Competitors Analysis of Cash and Cash Equivalents

CGEM · NASDAQ
CompanyCash and Cash Equivalents
CAGR 3Y
CAGR 5Y
CAGR 10Y
88.33M
-3.5%8.1%N/A 
145.00M
-1.7%0.1%N/A
CBLL logo
CeriBell, Inc.
NASDAQ:CBLL
40.48M
5.5%N/AN/A
EHAB logo
Enhabit, Inc.
NYSE:EHAB
43.60M
16.7%51.9%N/A
118.21M
31.7%33.0%12.9%
182.53M
-21.3%-14.9%N/A
169.74M
52.9%47.8%N/A
9.66M
10.8%-37.4%15.8%
Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Fair Value Envelope

CGEM · NASDAQ

Our analysis suggests that CGEM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $15.21, this represents a potential HIDDEN relative to our calculated worth for Cullinan Therapeutics, Inc..

Intrinsic Value
Current Price: $15.21